Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting

NCT06339255 is registered in ClinicalTrials.gov with Paolo Corradini as lead sponsor.

NCT NCT06339255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting
Lead sponsor
Paolo Corradini
Phase
Observational
Overall status
Recruiting
Start date
October 30, 2019
Completion date
December 31, 2029
Enrollment
5,300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse low grade b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl)